Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Sedana Medical AB ( (SE:SEDANA) ).
Sedana Medical AB announced that Chief Financial Officer Johan Spetz will leave the company to pursue a career opportunity outside the life science sector after serving in the role since March 2022. Spetz, credited by the CEO with playing a central role in the company’s transformation, improved performance, and achievements such as reaching EBITDA break-even in Europe and advancing preparations for a future US launch, will remain in post until a successor is appointed or until 19 June 2026 to ensure continuity, while the company has already started the recruitment process for a new CFO, signaling an orderly leadership transition with limited immediate disruption for operations and stakeholders.
The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK10.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.
More about Sedana Medical AB
Sedana Medical AB is a listed Swedish medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated intensive care patients, combining its Sedaconda ACD medical device with the Sedaconda (isoflurane) pharmaceutical. Founded in 2005 and headquartered in Stockholm, the company sells directly in key European markets including Benelux, France, Germany, Great Britain and Spain, and operates through distributors across the rest of Europe as well as in Asia, Australia, Canada, and South- and Central America.
Average Trading Volume: 213,086
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.04B
For an in-depth examination of SEDANA stock, go to TipRanks’ Overview page.